Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma

[1]  M. Christie,et al.  Loss of NF‐&kgr;B1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT‐1‐Dependent Manner , 2018, Immunity.

[2]  J. Ahn,et al.  Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study , 2018, American journal of hematology.

[3]  Ying Zhang,et al.  STAT1 in cancer: friend or foe? , 2017, Discovery medicine.

[4]  D. Gutmann,et al.  Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1‐associated malignant peripheral nerve sheath tumors , 2017, Cancer.

[5]  C. V. D. Schoot,et al.  Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences , 2017, Leukemia.

[6]  A. Look,et al.  Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia , 2017, British journal of haematology.

[7]  T. Waldmann,et al.  Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations , 2017, Proceedings of the National Academy of Sciences.

[8]  Daniel J. Weisenberger,et al.  Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling , 2016, Cell reports.

[9]  A. Khwaja,et al.  Next-generation sequencing identifies a novel ELAVL1–TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208 , 2016, Leukemia & lymphoma.

[10]  S. Verstovsek,et al.  Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib , 2016, Cancer Chemotherapy and Pharmacology.

[11]  S. Mian,et al.  Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress , 2016, Nature Communications.

[12]  J. French,et al.  Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials , 2015, Arthritis Research & Therapy.

[13]  A. Look,et al.  HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia , 2015, Leukemia.

[14]  Haifeng Zhang,et al.  STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. , 2015, Blood.

[15]  Suzanne D Turner,et al.  Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation , 2015, The Journal of pathology.

[16]  A. Rosenwald,et al.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. , 2015, Cancer cell.

[17]  K. Elenitoba-Johnson,et al.  A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. , 2014, Blood.

[18]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[19]  T. Rülicke,et al.  Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance , 2014, Transgenic Research.

[20]  Adam R. Johnson,et al.  A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors , 2013, The Journal of Immunology.

[21]  Angela G. Fleischman,et al.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.

[22]  K. Khazaie,et al.  Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells* , 2013, The Journal of Biological Chemistry.

[23]  T. Rülicke,et al.  TYK2 Kinase Activity Is Required for Functional Type I Interferon Responses In Vivo , 2012, PloS one.

[24]  V. Poli,et al.  STAT1 and STAT3 in tumorigenesis , 2012, JAK-STAT.

[25]  R. Advani,et al.  A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies , 2011, Clinical Cancer Research.

[26]  V. Sexl,et al.  Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. , 2011, Frontiers in bioscience.

[27]  W. Wilson,et al.  A novel role for IL-22R1 as a driver of inflammation. , 2011, Blood.

[28]  A. Rosenwald,et al.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. , 2010, Blood.

[29]  R. Weichselbaum,et al.  COOPERATIVITY OF THE MUC1 ONCOPROTEIN AND STAT1 PATHWAY IN POOR PROGNOSIS HUMAN BREAST CANCER , 2009, Oncogene.

[30]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Bernard Roizman,et al.  Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. , 2007, Cancer research.

[32]  James B. Mitchell,et al.  Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. , 2007, Cancer research.

[33]  R. Lai,et al.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. , 2006, Blood.

[34]  D. Alexander,et al.  CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. , 2006, Anticancer research.

[35]  G. Freeman,et al.  Tyk2 Negatively Regulates Adaptive Th1 Immunity by Mediating IL-10 Signaling and Promoting IFN-γ-Dependent IL-10 Reactivation1 , 2006, The Journal of Immunology.

[36]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[37]  K. Maclennan,et al.  Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase , 2003, Oncogene.

[38]  T. McDonnell,et al.  Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma , 2003, Oncogene.

[39]  C. Gambacorti-Passerini,et al.  Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. , 2003, Experimental hematology.

[40]  G. Inghirami,et al.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. , 2003, Blood.

[41]  Diane Lejeune,et al.  Interleukin-22 (IL-22) Activates the JAK/STAT, ERK, JNK, and p38 MAP Kinase Pathways in a Rat Hepatoma Cell Line , 2002, The Journal of Biological Chemistry.

[42]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[43]  T. McDonnell,et al.  Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. , 2002, The American journal of pathology.

[44]  T. McDonnell,et al.  Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. , 2001, The American journal of pathology.

[45]  H. Pircher,et al.  Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.

[46]  C. Copie-Bergman,et al.  Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. , 1998, The American journal of pathology.

[47]  P. Nowell,et al.  Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[49]  M. Fellous,et al.  A protein tyrosine kinase in the interferon α β signaling pathway , 1992, Cell.

[50]  E. Boel,et al.  Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides , 1992, In Vitro Cellular & Developmental Biology - Animal.

[51]  T. Shows,et al.  tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.

[52]  Mathias Müller,et al.  Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. , 2017, Cytokine.

[53]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[54]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[55]  P. Gélébart,et al.  Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma , 2008, Leukemia.